Recent News News

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer

(December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual... Continue Reading


Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors

(December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented... Continue Reading


Choice of surgery may affect quality of life for young breast cancer survivors

(December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research... Continue Reading


Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation

(November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata... Continue Reading


Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment

(November 28, 2018)

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker... Continue Reading


FDA Approves Venclexta Combination for AML in Adults

(November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid... Continue Reading


Patients with rare, incurable digestive tract cancers respond to new drug combination

(November 19, 2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some... Continue Reading


Tivozanib for Renal Cell Cancer

(November 16, 2018)

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth... Continue Reading


Keytruda Immunotherapy for Treatment of Liver Cancer

(November 13, 2018)

According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been... Continue Reading


U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

(November 12, 2018)

The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients... Continue Reading


Next Page »